Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5233MR)

This product GTTS-WQ5233MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5233MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ582MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ6989MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ9867MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ1886MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ3929MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ1603MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ488MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ1800MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW